These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 7912978)
21. Discordance between EGFR expression and clinicopathologic parameters of colorectal adenocarcinoma in Taiwan. Tsai WC; Lin CK; Lee HS; Chen A; Nieh S; Yu CP; Wu CC; Jao SW; Jin JS Chin J Physiol; 2012 Oct; 55(5):352-60. PubMed ID: 23282210 [TBL] [Abstract][Full Text] [Related]
22. Detection of cancer clones in human colorectal adenoma as revealed by increased DNA instability and other bio-markers. Jin Y; Sun A; Noriki S; Imamura Y; Fukuda M Eur J Histochem; 2007; 51(1):1-10. PubMed ID: 17548263 [TBL] [Abstract][Full Text] [Related]
23. Expression of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) and p53 tumor suppressor in dysplastic progression and adenocarcinoma in Barrett esophagus. Hanas JS; Lerner MR; Lightfoot SA; Raczkowski C; Kastens DJ; Brackett DJ; Postier RG Cancer; 1999 Sep; 86(5):756-63. PubMed ID: 10463972 [TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical study of oncogene product ras p21, c-myc and growth factor EGF in breast carcinomas. Mizukami Y; Nonomura A; Noguchi M; Taniya T; Koyasaki N; Saito Y; Hashimoto T; Matsubara F; Yanaihara N Anticancer Res; 1991; 11(4):1485-94. PubMed ID: 1660689 [TBL] [Abstract][Full Text] [Related]
25. [The results of p53 immunostaining in colorectal adenomas, early cancers, advanced cancers and their hepatic metastasis]. Saigusa N; Maruyama K; Sugimura H; Endoh Y; Baba S Gan To Kagaku Ryoho; 1996 Jun; 23 Suppl 2():159-63. PubMed ID: 8678561 [TBL] [Abstract][Full Text] [Related]
26. Clinical importance of p53 protein in gall bladder carcinoma and its precursor lesions. Wee A; Teh M; Raju GC J Clin Pathol; 1994 May; 47(5):453-6. PubMed ID: 8027399 [TBL] [Abstract][Full Text] [Related]
27. EGFR, HER-2/neu, cyclin D1, p21 and p53 in correlation to cell proliferation and steroid hormone receptor status in ductal carcinoma in situ of the breast. Lebeau A; Unholzer A; Amann G; Kronawitter M; Bauerfeind I; Sendelhofert A; Iff A; Löhrs U Breast Cancer Res Treat; 2003 May; 79(2):187-98. PubMed ID: 12825853 [TBL] [Abstract][Full Text] [Related]
28. Characterisation of oestrogen receptor, progesterone receptor, trefoil factor 1, and epidermal growth factor and its receptor in pancreatic cystic neoplasms and pancreatic ductal adenocarcinoma. Yeh TS; Jan YY; Chiu CT; Ho YB; Chen TC; Lee KF; Chan KM; Hsu JC; Hwang TL; Chen MF Gut; 2002 Nov; 51(5):712-6. PubMed ID: 12377812 [TBL] [Abstract][Full Text] [Related]
29. High c-erbB-2 protein level in colorectal adenocarcinomas correlates with clinical parameters. Kapitanovic S; Spaventi R; Poljak L; Kapitanovic M; Pavelic ZP; Gluckman JL; Spaventi S; Pavelic K Cancer Detect Prev; 1994; 18(2):97-101. PubMed ID: 7912991 [TBL] [Abstract][Full Text] [Related]
30. Expression of cyclin E in colorectal adenomas and adenocarcinomas: correlation with expression of Ki-67 antigen and p53 protein. Yasui W; Kuniyasu H; Yokozaki H; Semba S; Shimamoto F; Tahara E Virchows Arch; 1996 Sep; 429(1):13-9. PubMed ID: 8865848 [TBL] [Abstract][Full Text] [Related]
31. Colonic mucin-carbohydrate components in colorectal tumors and their possible relationship to MUC2, p53 and DCC immunoreactivities. Hara A; Saegusa M; Mitomi H; Kurihara M; Ishihara K; Hotta K; Okayasu I Pathol Res Pract; 2000; 196(3):159-66. PubMed ID: 10729920 [TBL] [Abstract][Full Text] [Related]
32. Expression of mdm2 and p53 in epithelial neoplasms of the colorectum. Hao XP; Günther T; Roessner A; Price AB; Talbot IC Mol Pathol; 1998 Feb; 51(1):26-9. PubMed ID: 9624416 [TBL] [Abstract][Full Text] [Related]
33. Abberant crypt foci -- importance in colorectal carcinogenesis and expression of p53 and mdm2: a changing concept. Das P; Jain D; Vaiphei K; Wig JD Dig Dis Sci; 2008 Aug; 53(8):2183-8. PubMed ID: 18080767 [TBL] [Abstract][Full Text] [Related]
34. Clinicopathological and molecular features of sessile serrated adenomas with dysplasia or carcinoma. Bettington M; Walker N; Rosty C; Brown I; Clouston A; McKeone D; Pearson SA; Leggett B; Whitehall V Gut; 2017 Jan; 66(1):97-106. PubMed ID: 26475632 [TBL] [Abstract][Full Text] [Related]
35. An immunohistochemical study of the simultaneous expression of bcl-2 and p53 oncoproteins in epithelial tumors of the colon and rectum. Mosnier JF; Perret AG; Vindimian M; Dumollard JM; Balique JG; Perpoint B; Boucheron S Arch Pathol Lab Med; 1996 Jul; 120(7):654-9. PubMed ID: 8757470 [TBL] [Abstract][Full Text] [Related]
36. p53 immunoreactive stain and early colorectal adenocarcinomas. Hirota S; Kudo S; Hosobe S; Kobayashi T; Himori M; Ikeda M; Takemoto Y; Nomoto M; Aoyagi Y; Asakura H Eur J Cancer; 1995 Dec; 31A(13-14):2220-2. PubMed ID: 8652246 [TBL] [Abstract][Full Text] [Related]
37. Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Archer SG; Eliopoulos A; Spandidos D; Barnes D; Ellis IO; Blamey RW; Nicholson RI; Robertson JF Br J Cancer; 1995 Nov; 72(5):1259-66. PubMed ID: 7577479 [TBL] [Abstract][Full Text] [Related]
38. Basal cell adenocarcinoma of the salivary glands: comparison with basal cell adenoma through assessment of cell proliferation, apoptosis, and expression of p53 and bcl-2. Nagao T; Sugano I; Ishida Y; Hasegawa M; Matsuzaki O; Konno A; Kondo Y; Nagao K Cancer; 1998 Feb; 82(3):439-47. PubMed ID: 9452259 [TBL] [Abstract][Full Text] [Related]
39. Immunohistochemical detection of p53 tumor suppressor gene protein in canine epithelial colorectal tumors. Wolf JC; Ginn PE; Homer B; Fox LE; Kurzman ID Vet Pathol; 1997 Sep; 34(5):394-404. PubMed ID: 9381650 [TBL] [Abstract][Full Text] [Related]
40. [P53 protein in adenocarcinoma of the large intestine]. Paluszkiewicz P; Pawłowska-Wakowicz B; Cybulski M; Berbeć H Wiad Lek; 1997; 50 Suppl 1 Pt 1():87-91. PubMed ID: 9446410 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]